Hôpital Européen Marseille
35
11
12
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
5 terminated/withdrawn out of 35 trials
73.7%
-12.9% vs industry average
3%
1 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (35)
Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital
Role: lead
Detection of Small Fiber Neuropathies by the Non-invasive SUDOSCAN Method During Chronic Autoimmune Pathologies and / or Unexplained Pain Syndromes
Role: lead
Response of the Autonomic Nervous System to Auricular Stimulation of the Vagus Nerve (x)
Role: lead
Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: "Proof of Concept" Study (CoviDetectionDog)-Covid-19
Role: lead
Self and Body Perception in Otoneurological Disorders: Translation and Validation of Measurement Scales
Role: lead
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children
Role: collaborator
Study on the Management of COMISA
Role: collaborator
National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis
Role: collaborator
Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? A Study Comparing Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome and Patients With Cardiac Diseases Who Underwent an Exercise Test.
Role: lead
Impact of ERCS on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service
Role: lead
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Role: lead
Efficacy Study of Ifabond in Breast Cancer Surgery
Role: lead
Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients
Role: lead
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
Role: lead
Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV
Role: lead
Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy
Role: lead
Gut Microbiota Dysbiosis and Translocation During IBD and Parkinson
Role: lead
Impact of Onco-sexology Support on the Quality of Life of Patients Newly Diagnosed for Cancer
Role: lead
Treatment of Episodic Migraine With AURICular Neuromodulation
Role: lead
Covid-19 Respiratory Sequelae French Cohort
Role: collaborator